C

Cresco Labs Inc
CNSX:CL

Watchlist Manager
Cresco Labs Inc
CNSX:CL
Watchlist
Price: 1.65 CAD -6.78%
Market Cap: 867.2m CAD

Relative Value

The Relative Value of one CL stock under the Base Case scenario is 3.88 CAD. Compared to the current market price of 1.65 CAD, Cresco Labs Inc is Undervalued by 57%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CL Relative Value
Base Case
3.88 CAD
Undervaluation 57%
Relative Value
Price
C
Worst Case
Base Case
Best Case

Multiples Across Competitors

CL Competitors Multiples
Cresco Labs Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Cresco Labs Inc
CNSX:CL
867.2m CAD 0.9 -12 5.7 9.4
US
Eli Lilly and Co
NYSE:LLY
984.9B USD 16.8 54.3 36.4 39
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 5.8 -157.8 0.4 1.9
US
Johnson & Johnson
NYSE:JNJ
525.1B USD 5.6 20.5 16.7 21.7
CH
Roche Holding AG
SIX:ROG
273.5B CHF 4.4 28.9 12.3 14.4
UK
AstraZeneca PLC
LSE:AZN
207.4B GBP 0 0.3 0 0
CH
Novartis AG
SIX:NOVN
219.1B CHF 5 19.3 15.5 20
US
Merck & Co Inc
NYSE:MRK
272.2B USD 4.3 14.4 10.2 12.1
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.3 16.1 11.2 13.1
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
US
Pfizer Inc
NYSE:PFE
145.1B USD 2.3 14.7 7.5 10.2
P/E Multiple
Earnings Growth PEG
US
C
Cresco Labs Inc
CNSX:CL
Average P/E: 21.1
Negative Multiple: -12
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.3
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -157.8 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.5
29%
0.7
CH
Roche Holding AG
SIX:ROG
28.9
29%
1
UK
AstraZeneca PLC
LSE:AZN
0.3
37%
0
CH
Novartis AG
SIX:NOVN
19.3
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.4
15%
1
DK
Novo Nordisk A/S
CSE:NOVO B
16.1
3%
5.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.7
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
C
Cresco Labs Inc
CNSX:CL
Average EV/EBITDA: 41.9
5.7
0%
N/A
US
Eli Lilly and Co
NYSE:LLY
36.4
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
0.4
36%
0
US
Johnson & Johnson
NYSE:JNJ
16.7
9%
1.9
CH
Roche Holding AG
SIX:ROG
12.3
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
0
10%
0
CH
Novartis AG
SIX:NOVN
15.5
6%
2.6
US
Merck & Co Inc
NYSE:MRK
10.2
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
11.2
1%
11.2
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A